LY3526318

LY3526318 is an orally active, selective TRPA1 antagonist (IC50=5-6μM) . LY3526318 blocks TRPA1 channels, inhibits pain signal transduction mediated by the channel, and exerts analgesic activity. LY3526318 is mainly used in the research of chronic pain-related fields, such as diabetic peripheral neuropathy, chronic low back pain, and pain caused by osteoarthritis[1][2].

Product Specifications

CAS Number

[1889218-34-1]

UNSPSC

12352005

Target

TRP Channel

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Field of Research

Inflammation/Immunology; Neurological Disease

Purity

99.92

Solubility

DMSO : 80 mg/mL (ultrasonic)

Smiles

FC(F)(F)C1=NC=C(C=N1)C2=NC(NC([C@@H](N3C4=C(N=C3)N(C(N(C4=O)CC5=NC(C)=NO5)=O)C)C)=O)=CC=C2

Molecular Formula

C23H19F3N10O4

Molecular Weight

556.46

References & Citations

[1]Bamps D, et al. TRPA1 Antagonist LY3526318 Inhibits the Cinnamaldehyde-Evoked Dermal Blood Flow Increase: Translational Proof of Pharmacology. Clin Pharmacol Ther. 2023 Nov;114 (5) :1093-1103.|[2]Broad LM, et al. Preclinical and clinical evaluation of a novel TRPA1 antagonist LY3526318. Pain. 2025 Apr 18.